サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1206364

欧州の過活動膀胱治療の2028年までの市場予測-地域別分析-薬物療法別、疾患タイプ別

Europe Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type
出版日: | 発行: The Insight Partners | ページ情報: 英文 153 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州の過活動膀胱治療の2028年までの市場予測-地域別分析-薬物療法別、疾患タイプ別
出版日: 2023年01月13日
発行: The Insight Partners
ページ情報: 英文 153 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の過活動膀胱治療市場は、2022年の11億1,105万米ドルから2028年には13億1,855万米ドルに成長すると予測され、2022年から2028年までのCAGRは2.9%と推定されています。

尿路感染症の増加により、欧州の過活動膀胱治療市場の成長が加速

尿路感染症（UTI）は、膀胱壁の筋肉の活動を活発化させ、過活動膀胱と同様の症状を引き起こすことがあります。UTIの原因菌は尿路上皮細胞の内壁に存在し、自然免疫力が低下した状態で宿主体を攻撃します。尿路結石を繰り返す人は、排尿機能障害や十字筋過活動が認められ、これらの機能異常は、尿路上皮バリアの完全性をさらに損ないます。尿路結石は、国内において外来診療の受診理由としては8番目、救急外来の受診理由としては5番目に多い疾患です。さらに、National Institute for Health and Care Excellenceの組織によると、UTIは英国で最も一般的な院内感染症の一つであり、全感染症の～23％を占めています。BMC Family Practiceによると、2019年のオランダでは、UTIの診察はED受診の~2%を占めています。同様に、フランスでは、毎年～400～600万人がUTIに悩まされています。このように、UTIの発生率の増加は、UTIと過活動膀胱の関連性と相まって、欧州の過活動膀胱治療市場の成長に寄与する顕著な要因の1つとなっています。

欧州の過活動膀胱治療市場の概要

欧州の過活動膀胱治療市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。欧州は、世界の過活動膀胱治療市場において重要な位置を占めており、予測期間中に大幅なCAGRを記録すると推定されています。老年人口の存在による過活動膀胱治療への需要の高まりが、欧州の市場成長を牽引しています。さらに、尿路機能を阻害する神経疾患や糖尿病の蔓延が、今後数年間、過活動膀胱治療の成長に機会をもたらすと考えられます。英国議会のデータによると、2019年には英国総人口の約5分の1が65歳以上となりました。その上、この年齢層の人数は2009年から2019年にかけて23%増加しましたが、同じ期間に英国の総人口は7%しか増加しませんでした。Diabetes UKによると、2019年に糖尿病と診断された人は～390万人で、2021年には470万人に達します。英国における糖尿病の有病率の上昇と高齢者人口の増加は、過活動膀胱状態の症例の急増につながり、それによってその治療に対する需要を煽ります。

欧州の過活動膀胱治療市場の収益と2028年までの予測（百万米ドル）

欧州の過活動膀胱治療市場のセグメンテーション

欧州の過活動膀胱治療市場は、薬物療法、疾患タイプ、国別に分類されています。

欧州の過活動膀胱治療市場は、薬物療法、疾患タイプ、国別に細分化されます。

薬物療法に基づき、市場は抗コリン薬、ミラベグロン、ボトックス、神経刺激、膀胱内注入に区分されます。ミラベグロンセグメントは、2022年に市場で最大のシェアを登録しました。疾患タイプに基づき、欧州の過活動膀胱治療市場は特発性過活動膀胱と神経原性膀胱に二分されます。2022年の市場では、特発性過活動膀胱のセグメントが大きなシェアを占めています。国別に見ると、欧州の過活動膀胱治療市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に分類されます。2022年は英国が市場を独占しています。AbbVie Inc、Alembic Pharmaceuticals Limited、Astellas Pharma Inc、Endo Pharmaceuticals Inc、久光製薬株式会社、Medtronic Plc、Pfizer Inc、Teva Pharmaceutical Industries Ltdは、欧州の過活動膀胱治療市場で事業を展開している主要企業です。

目次

第1章 イントロダクション

  • 調査範囲
  • 洞察パートナーズの調査報告書ガイダンス
  • 市場セグメンテーション
    • 欧州の過活動膀胱治療薬市場-薬物療法別
    • 欧州の過活動膀胱治療薬市場-疾患タイプ別
    • 欧州の過活動膀胱治療市場：国別

第2章 欧州の過活動膀胱治療市場：主要なポイント

第3章 調査手法

  • 調査範囲
  • 2次調査（セカンダリーリサーチ
  • 1次調査

第4章 欧州の過活動膀胱治療市場- 市場情勢

  • 欧州PEST分析
  • 専門家別オピニオン

第5章 欧州の過活動膀胱治療市場-主要市場力学

  • 市場促進要因
    • 尿失禁の有病率の増加
    • 尿路感染症の発生率の増加
  • 主な市場抑制要因
    • 治療薬のリコール
  • 主な市場機会
    • M&A（合併・買収）の増加
  • 今後の動向
    • 強力な医薬品パイプラインと新規治療薬の相次ぐ上市
  • 影響度分析

第6章 欧州の過活動膀胱治療市場-欧州分析

  • 欧州の過活動膀胱治療市場収益と予測・分析

第7章 過活動膀胱治療薬の欧州市場分析・2028年予測- 薬物療法別

  • 欧州の過活動膀胱治療薬市場、薬物療法別2021年・2028年（%）
  • ミラベグロン
  • ボトックス
  • 神経刺激療法
  • 抗コリン薬
  • 膀胱内注入

第8章 欧州の過活動膀胱治療市場の分析と2028年までの予測（疾患タイプ別

  • 欧州の過活動膀胱治療市場：疾患タイプ別2021年・2028年（%）
  • 特発性過活動膀胱
  • 神経因性過活動膀胱（Neurogenic Overactive Bladder

第9章 過活動膀胱治療薬市場の収益と2028年までの予測- 国別分析

    • 欧州
      • 英国
      • ドイツ
      • フランス
      • イタリア
      • スペイン
      • その他欧州

第10章 過活動膀胱治療市場-業界情勢

  • 有機的な展開

第11章 企業プロファイル

  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc
  • AbbVie Inc
  • Teva Pharmaceutical Industries Ltd
  • Endo Pharmaceuticals Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic Plc
  • Pfizer Inc

第12章 付録

  • The Insight Partners について
  • 用語集
図表

List Of Tables

  • Table 1. UK: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. UK: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. UK: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. UK: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Germany: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Germany: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Germany: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Germany: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. France: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. France: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. France: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. France: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Italy: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Italy: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Italy: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Italy: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Spain: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Spain: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Spain: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Spain: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Rest of Europe: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Rest of Europe: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Rest of Europe: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Rest of Europe: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Organic Developments Done by Companies
  • Table 26. Glossary of Terms

List Of Figures

  • Figure 1. Europe Overactive Bladder Treatment Market Segmentation
  • Figure 2. Europe Overactive Bladder Treatment Market Segmentation, By Country
  • Figure 3. Europe Overactive Bladder Treatment Market Overview
  • Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in Europe Overactive Bladder Treatment market
  • Figure 5. UK Is Expected to Show Remarkable Growth During the Forecast Period
  • Figure 7. Europe: PEST Analysis
  • Figure 8. Europe Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
  • Figure 9. Europe Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2019- 2028
  • Figure 10. Europe Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
  • Figure 11. Mirabegron: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 12. Botox: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 13. Neurostimulation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 14. Transcutaneous Sacral Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 15. Transcutaneous Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
  • Figure 16. Percutaneous Posterior Tibial Nerve: Europe Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
  • Figure 17. Others: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
  • Figure 18. Anticholinergics: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 19. Solifenacin: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 20. Oxybutynin: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 21. Fesoterodine: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 22. Darifenacin: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 23. Tolterodine: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
  • Figure 24. Trospium: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
  • Figure 25. Other Anticholinergics: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
  • Figure 26. Intravesical Instillation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 27. Europe Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
  • Figure 28. Idiopathic: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 29. Neurogenic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 30. Europe: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 31. Europe: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
  • Figure 32. UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
目次
Product Code: BMIRE00027805

The Europe overactive bladder treatment market is expected to grow from US$ 1,111.05 million in 2022 to US$ 1,318.55 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2022 to 2028.

Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth

Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4-6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.

Europe Overactive Bladder Treatment Market Overview

The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament's data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.

Europe Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

Europe Overactive Bladder Treatment Market Segmentation

The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.

The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022. Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022. Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022. AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe overactive bladder treatment market
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Table Of Contents

1. Introduction

  • 1.1 Study Scope
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe Overactive Bladder Treatment Market- By Pharmacotherapy
    • 1.3.2 Europe Overactive Bladder Treatment Market- By Disease Type
    • 1.3.3 Europe Overactive Bladder Treatment Market - By Country

2. Europe Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Overactive Bladder Treatment Market - Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis
  • 4.3 Expert Opinion

5. Europe Overactive Bladder Treatment Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Prevalence of Urinary Incontinence
    • 5.1.2 Growing Incidence of Urinary Tract Infections
  • 5.2 Key Market Restraints
    • 5.2.1 Recalls of Therapeutic Drugs
  • 5.3 Key Market Opportunities
    • 5.3.1 Increasing Number of Mergers and Acquisitions
  • 5.4 Future Trends
    • 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
  • 5.5 Impact analysis

6. Europe Overactive Bladder Treatment Market - Europe Analysis

  • 6.1 Europe Overactive Bladder Treatment Market Revenue Forecast and Analysis

7. Europe Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

  • 7.1 Overview
  • 7.2 Europe Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
  • 7.3 Mirabegron
    • 7.3.1 Overview
    • 7.3.2 Mirabegron: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Botox
    • 7.4.1 Overview
    • 7.4.2 Botox: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Neurostimulation
    • 7.5.1 Overview
    • 7.5.2 Neurostimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.3 Transcutaneous Sacral Nerve Stimulation
      • 7.5.3.1 Overview
      • 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.4 Transcutaneous Tibial Nerve Stimulation
      • 7.5.4.1 Overview
      • 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
      • 7.5.5.1 Overview
      • 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.6 Others
      • 7.5.6.1 Overview
      • 7.5.6.2 Others: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
  • 7.6 Anticholinergics
    • 7.6.1 Overview
    • 7.6.2 Anticholinergics: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.3 Solifenacin
      • 7.6.3.1 Overview
      • 7.6.3.2 Solifenacin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.4 Oxybutynin
      • 7.6.4.1 Overview
      • 7.6.4.2 Oxybutynin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.5 Fesoterodine
      • 7.6.5.1 Overview
      • 7.6.5.2 Fesoterodine: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.6 Darifenacin
      • 7.6.6.1 Overview
      • 7.6.6.2 Darifenacin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.7 Tolterodine
      • 7.6.7.1 Overview
      • 7.6.7.2 Tolterodine: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.8 Trospium
      • 7.6.8.1 Overview
      • 7.6.8.2 Trospium: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.9 Other Anticholinergics
      • 7.6.9.1 Overview
      • 7.6.9.2 Other Anticholinergics: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Intravesical Instillation
    • 7.7.1 Overview
    • 7.7.2 Intravesical Instillation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

8. Europe Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

  • 8.1 Overview
  • 8.2 Europe Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
  • 8.3 Idiopathic Overactive Bladder
    • 8.3.1 Overview
    • 8.3.2 Idiopathic: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
  • 8.4 Neurogenic Overactive Bladder
    • 8.4.1 Overview
    • 8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

  • 9.1 Overview
    • 9.1.2 Europe: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
      • 9.1.2.1 UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.1.1 UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.1.2 UK: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.1.2.1 UK: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.1.2.2 UK: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.1.3 UK: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.2.2 Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.2.1 Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.2.2 Germany: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.2.2.1 Germany: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.2.2.2 Germany: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.2.3 Germany: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.2.3 France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.3.1 France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.3.2 France: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.3.2.1 France: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.3.2.2 France: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.3.3 France: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.2.4 Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.4.1 Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.4.2 Italy: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.4.2.1 Italy: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.4.2.2 Italy: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.4.3 Italy: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.2.5 Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.5.1 Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.5.2 Spain: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.5.2.1 Spain: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.5.2.2 Spain: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.5.3 Spain: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.2.6 Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.6.1 Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.6.2 Rest of Europe: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.6.2.1 Rest of Europe: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.6.2.2 Rest of Europe: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.2.6.3 Rest of Europe: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)

10. Overactive Bladder Treatment Market- Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Developments
    • 10.2.1 Overview

11. Company Profiles

  • 11.1 Alembic Pharmaceuticals Limited
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Astellas Pharma Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 AbbVie Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Teva Pharmaceutical Industries Ltd
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Endo Pharmaceuticals Inc.
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Hisamitsu Pharmaceutical Co., Inc.
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Medtronic Plc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Pfizer Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms